Risk factors for cardiovascular disease in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 24, Issue 2, 2012, Pages 171-176

  Gabriel, Sherine E ^a,b   Crowson, Cynthia S ^a,c  

^a Division of Rheumatology   (United States)

^b Department of Health Sciences Research ^*  (United States)

^c MAYO CLINIC   (United States)

Author keywords

cardiovascular risk factors; rheumatoid arthritis

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CELECOXIB; CORTICOSTEROID; CYCLOSPORIN; DICLOFENAC; ETORICOXIB; GLUCOCORTICOID; GOLD; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; IBUPROFEN; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUMIRACOXIB; METHOTREXATE; NAPROXEN; RITUXIMAB; ROFECOXIB; TOCILIZUMAB;

BLOOD PRESSURE REGULATION; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; DISEASE ACTIVITY; DYSLIPIDEMIA; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYPERTENSION; IMMOBILIZATION; INCIDENCE; JOINT RADIOGRAPHY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMOKING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84857054984     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834ff2fd     Document Type: Review

References (73)

1. Kozera L, Andrews J, Morgan AW. Cardiovascular risk and rheumatoid arthritis: The next step: Differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. Rheumatology (Oxford) 2011; 50:1944-1954.
2. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: Traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69:1920-1925.
3. Innala L, Moller B, Ljung L, et al. Cardiovascular events in early rheumatoid arthritis (RA) are a result of inflammatory burden and traditional risk factors: A five year prospective study. Arthritis Res Ther 2011; 13:R131.
4. Bergstrom U, Jacobsson LT, Nilsson JA, Berglund G, Turesson C. Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis. Rheumatology (Oxford) 2011; 50:2005-2013.
5. Boyer JF, Gourraud PA, Cantagrel A, et al Traditional risk factors in rheumatoid arthritis: A meta-Analysis. Joint Bone Spine 2011 78 179-183. This is a meta-Analysis of the prevalence of traditional cardiovascular risk factors in patients with rheumatoid arthritis compared with controls. It shows several risk factors for cardiovascular disease appear to be more prevalent in patients with rheumatoid arthritis, which may contribute to the increased cardiovascular disease observed in patients with rheumatoid arthritis.
6. Rojas-Serrano J, Perez LL, Garcia CG, et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis: A cohort study. Clin Rheumatol 2011; 30:1589-1593.
7. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373:659-672.
8. Klareskog L, Malmstrom V, Lundberg K, et al. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011; 23:92-98.
9. Serelis J, Panagiotakos DB, Mavrommati M, Skopouli FN. Cardiovascular disease is related to hypertension in patients with rheumatoid arthritis: A Greek cohort study. J Rheumatol 2011; 38:236-241.
10. Panoulas VF, Douglas KM, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46:1477-1482. (Pubitemid 47317098)
11. Semb AG, Kvien TK, Aastveit AH, et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis 2010; 69:1996-2001. This study demonstrated in a large sample that lipid levels are less predictive of myocardial infarction in patients with rheumatoid arthritis than in patients without rheumatoid arthritis.
12. Heldenberg D, Caspi D, Levtov O, et al. Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis. Clin Rheumatol 1983; 2:387-391.
13. Lorber M, Aviram M, Linn S, et al. Hypocholesterolaemia and abnormal highdensity lipoprotein in rheumatoid arthritis. Br J Rheumatol 1985; 24:250-255. (Pubitemid 15226488)
14. Lakatos J, Harsagyi A. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988; 21:93-96.
15. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53:551-552. (Pubitemid 24256991)
16. Myasoedova E, Maradit Kremers H, Fitz-Gibbon P, et al. Lipid profile improves with the onset of rheumatoid arthritis. Ann Rheum Dis 2009; 68 (Suppl 3):78.
17. Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69:1310-1314.
18. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: Roles of inflammation and dyslipidemia. J Autoimmun 2007; 28 (2-3):69-75. (Pubitemid 46670686)
19. Gonzalez A, Kremers HM, Crowson CS, et al. Do cardiovascular risk factors confer the samerisk for cardiovascular outcomes in rheumatoid arthritis patients as in nonrheumatoid arthritis patients? Ann Rheum Dis 2008; 67:64-69.
20. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis: The Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32:2311-2316. (Pubitemid 41780639)
21. Semb AG, Holme I, Kvien TK, Pedersen TR. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: An explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial. Rheumatology (Oxford) 2011; 50:324-329.
22. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial undertreatment of lipid-Associated cardiovascular risk? Ann Rheum Dis 2010; 69:683-688.
23. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: Mechanisms and the impact of treatment. Semin Arthritis Rheum 2009; 38:372-381.
24. Toms TE, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: The role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol 2010; 8:301-326.
25. Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: State of the art and future perspectives. Ann Rheum Dis 2011; 70:8-14.
26. van Sijl AM, Peters MJ, Knol DL, et al. The effect of TNF-Alpha blocking therapy on lipid levels in rheumatoid arthritis: A meta-Analysis. Semin Arthritis Rheum 2011; 41:393-400.
27. van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: Serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66:184-188. (Pubitemid 46226052)
28. Bartels CM, Kind AJ, Everett C, et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum 2011; 63:1221-1230.
29. Crowson CS, Myasoedova E, Davis JM 3rd, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 2011; 38:29-35.
30. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008; 196:756-763. (Pubitemid 351165786)
31. Gremese E, Ferraccioli G. The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10:582-589.
32. Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54:2765-2775. (Pubitemid 44497755)
33. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298:187-193. (Pubitemid 47057765)
34. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: Role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165:1624-1629. (Pubitemid 41124157)
35. Maradit Kremers HM, Nicola PJ, Crowson CS, et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004; 50:3450-3457. (Pubitemid 39488669)
36. Symmons DP, Bankhead CR, Harrison BJ, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40:1955-1961. (Pubitemid 27494654)
37. Voigt LF, Koepsell TD, Nelson JL, et al. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994; 5:525-532. (Pubitemid 24271621)
38. Pedersen M, Jacobsen S, Klarlund M, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-Antibodies against cyclic citrullinated peptides. Arthritis Res Ther 2006; 8:R133.
39. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68:242-245.
40. Dessein PH, Norton GR, Woodiwiss AJ, et al. Independent role of conventional cardiovascular risk factors as predictors of C-reactive protein concentrations in rheumatoid arthritis. J Rheumatol 2007; 34:681-688. (Pubitemid 46641371)
41. Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis: Association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010; 62:3173-3182. This study shows patients with rheumatoid arthritis have more abdominal adiposity despite no difference in body mass index compared with patients without rheumatoid arthritis, which has implications for understanding cardiovascular risk in rheumatoid arthritis.
42. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study. Arthritis Rheum 2008; 58:2268-2274.
43. Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009; 61:1571-1579.
44. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69:325-331. This paper details recommendations from a committee of experts for managing cardiovascular risk in patients with rheumatoid arthritis. While much work is still needed to better identify the cause of the excess cardiovascular risk in rheumatoid arthritis, this is a crucial step in the right direction toward managing cardiovascular risk in patients with rheumatoid arthritis.
45. Koenig W, Sund M, Filipiak B, et al. Plasma viscosity and the risk of coronary heart disease: Results from the MONICA-Augsburg Cohort Study, 1984 to 1992. Arterioscler Thromb Vasc Biol 1998; 18:768-772. (Pubitemid 28267657)
46. Szapary L, Horvath B, Marton Z, et al. Hemorheological disturbances in patients with chronic cerebrovascular diseases. Clin Hemorheol Microcirc 2004; 31:1-9. (Pubitemid 39093234)
47. Smith FB, Lee AJ, Fowkes FG, et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17:3321-3325. (Pubitemid 28016094)
48. Santos MJ, Pedro LM, Canhao H, et al. Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. Atherosclerosis 2011; 219:821-826. This study reports associations between hemorheological parameters and early stages of atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Abnormal rheological characteristics of blood may represent an additional mechanism contributing to atherosclerosis in patients with rheumatic diseases.
49. Marder W, Khalatbari S, Myles JD, et al. Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis. Ann Rheum Dis 2011; 70:1550-1555.
50. Rodriguez-Rodriguez L, Gonzalez-Juanatey C, Palomino-Morales R, et al. TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011; 216:125-130.
51. Davis JM 3rd, Knutson KL, Strausbauch MA, et al. A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum 2011; 63:1497-1506.
52. Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: A ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52:2293-2299. (Pubitemid 41117412)
53. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: A retrospective cohort study from disease onset. J Rheumatol 1999; 26:2562-2571.
54. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2005; 52:402-411. (Pubitemid 40220344)
55. Banerjee S, Compton AP, Hooker RS, et al. Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol 2008; 101:1201-1205.
56. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58:359-369. (Pubitemid 351294870)
57. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:76-80. (Pubitemid 46044863)
58. Liang KP, Kremers HM, Crowson CS, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009; 36:2462-2469.
59. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, et al. Association between anticyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61:419-424.
60. Tomasson G, Aspelund T, Jonsson T, et al. The effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2009; 69:1649-1654.
61. Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61:1580-1585.
62. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. Arthritis Rheum 2008; 58:2612-2621.
63. Farragher TM, Lunt M, Bunn DK, et al. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: Results from the Norfolk Arthritis Register. Ann Rheum Dis 2007; 66:486-492. (Pubitemid 46580469)
64. Aho K, Salonen JT, Puska P. Autoantibodies predicting death due to cardiovascular disease. Cardiology 1982; 69:125-129. (Pubitemid 12099919)
65. Goodson NJ, Brookhart AM, Symmons DP, et al. Nonsteroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis 2009; 68:367-372.
66. Trelle S, Reichenbach S, Wandael S, et al. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: Network meta-Analysis. Br Med J 2011; 342:c7086. doi: 10.1136/bmj.7086. This meta-Analysis shows that all nonsteroidal anti-inflammatory medications are associated with some degree of increased risk of cardiovascular disease.
67. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research. Ann Rheum Dis 2009; 68:1100-1104.
68. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology (Oxford) 2010; 49:295-307.
69. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Res Ther 2008; 10:R30.
70. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58:667-677. (Pubitemid 351364864)
71. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:576-582.
72. Turiel M, Tomasoni L, Sitia S, et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 2010; 28:e53-e64.
73. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004; 363:2015-2021. (Pubitemid 38781100)